Skip to main content
Log in

Treatment of cerebellar ataxia with 5-HT1A agonist

  • Review
  • Published:
The Cerebellum Aims and scope Submit manuscript

Abstract

Effective, pharmacologic approaches to the treatment of cerebellar ataxia are lacking or inadequate. We recently reported preliminary evidence that tandospirone citrate (tandospirone), a 5-HT1A agonist, improved cerebellar ataxia in patients with Machado-Joseph disease (MJD). In the course of that study, we found that such treatment also alleviated the pain associated with cold sensations in the legs, insomnia, anorexia, and depression, all of which are thought to be mediated through activation of the 5-HT1A receptor. In this paper, we reviewed the few published clinical trials that involved the use of 5-HT 1A receptor agonists for the treatment of cerebellar ataxia, and discussed the current theories regarding their mechanism of action. Cortical cerebellar atrophy (CCA) was reported, in a double-blind study, to be amenable to treatment with tandospirone. Other types of spinocerebellar degeneration (SCD) i.e., olivopontocerebellar atrophy (OPCA) and Machado-Joseph disease (MJD) have also been reported to respond to the drug, but these have been small studies. Responsive patients exhibited only mild ataxia. The doses of 5-HT1A agonists that have been used successfully ranged from 12.5 mg/day to 60 mg/day (or 1mg/kg), and were well tolerated by most patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Waragai M, Ogawara K, Takaya Y, Hayashi M. Efficacy of TRH-T for spinocerebellar degeneration —the relation between clinical features and effect of TRH therapy. Rinsho Shinkeigaku. 1997;37:587–94. [In Japanese]

    PubMed  CAS  Google Scholar 

  2. Kanazawa I, Satoyoshi E, Hirayama K, et al. Clinical evaluation of taltirelin hydrate (TA-0910) in patients with spinocerebellar degeneration —A multi-center double-blind comparative study with placebo. Rinsyo Iyaku. 1997; 13:4169–24. [In Japanese]

    Google Scholar 

  3. Fukuchi I, Asahi T, Kawashima K, Kawashima Y, Yamamura M, Matsuoka Y, Kinoshita K. Effects of Taltirelin hydrate (TA-0910), a novel thyrotropin-releasing hormone analog, onin vivo dopamine release and turnover in rat brain. Arzneimittelforschung. 1998;48:353–9.

    PubMed  CAS  Google Scholar 

  4. Trouillas P. L-5-Hydroxytryptophan treatment in cerebellar ataxia: Clinical and etiological correlations. Mov Disord. 1990;5(Suppl. 1):6.

    Google Scholar 

  5. Trouillas P, Brudon F, Adeleine P. Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan. A double-blind study with quantified data processing. Arch Neurol. 1988;45:1217–22.

    PubMed  CAS  Google Scholar 

  6. Lou JS, Goldfarb L, McShane L, Gatev P, Hallett M. Use of buspirone for treatment of cerebellar ataxia. An open-label study. Arch Neurol. 1995;52:982–8.

    PubMed  CAS  Google Scholar 

  7. Trouillas P, Xie J, Adeleine P, et al. Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy. Arch Neurol. 1997; 54:749–52.

    PubMed  CAS  Google Scholar 

  8. Trouillas P, Xie J, Adeleine P. Buspirone, a serotonergic 5-HT1A agonist, is active in cerebellar ataxia. A new fact in favor of the serotonergic theory of ataxia. Prog Brain Res. 1997;114:589–99.

    Article  PubMed  CAS  Google Scholar 

  9. Friedman JH. Machado-Joseph disease/spinocerebellar ataxia 3 responsive to buspirone. Mov Disord. 1997;12:613–14.

    Article  PubMed  CAS  Google Scholar 

  10. Saito Y, Miwa S, Yamana T, Hasegawa Y, Takagi S. Clinical therapeutical trial of oral tandospirone for cerebellar ataxia. Nagoya Shiritu Byouin Kiyou. 1998;21:5–8. [In Japanese]

    Google Scholar 

  11. Takei A, Honma S, Kawashima A, et al. Beneficial effects of tandospirone on ataxia of a patient with Machado-Joseph disease. Psychiatry Clin Neurosci. 2002;56:181–5.

    Article  PubMed  Google Scholar 

  12. Takei A, Fukazawa T, Hamada T, Yabe I, Tashiro K. ‘Drug holiday’ effects of tandospirone in a patient with Machado-Joseph disease. Psychiatry Clin Neurosci. 2003;57:607–8.

    Article  PubMed  Google Scholar 

  13. Takei A, Fukazawa T, Hamada T, Sohma H, Yabe I, Sasaki H, Tashiro K. Effects of tandospirone on ‘5-HT1A receptor-associated symptoms’ in patients with Machado-Joseph disease. An open-label study. Clin Neuropharmacol. 2004;27:9–13.

    Article  PubMed  CAS  Google Scholar 

  14. Traber J, Glaser T. 5-HT1A-related anxiolytics. Trends Pharmacol Sci. 1987;8:432–7.

    Article  CAS  Google Scholar 

  15. Parks CL, Robinson PS, Sibille E, Shenk T, Toth M. Increased anxiety of mice lacking the serotonin1A receptor. Proc Natl Acad Sci USA. 1998;95:10734–9.

    Article  PubMed  CAS  Google Scholar 

  16. Bjorvatn B, Fagerland S, Eid T, Ursin R. Sleep/waking effects of a selective 5-HT1A receptor agonist given systemically as well as perfused in the dorsal raphe nucleus in rats. Brain Res. 1997;770:81–8.

    Article  PubMed  CAS  Google Scholar 

  17. Sørensen E, Grønli J, Bjorvatn B, Bjørkum A, Ursin R. Sleep and waking following microdialysis perfusion of the selective 5-HT1A receptor antagonist p-MPPI into the dorsal raphe nucleus in the freely moving rat. Brain Res. 2001; 897:122–30.

    Article  PubMed  Google Scholar 

  18. Vickers SP, Clifton PG, Dourish CT. Behavioural evidence that d-fenfluramine-induced anorexia in the rat is not mediated by the 5-HT1A receptor subtype. Psychopharmacology. 1996;125:168–75.

    Article  PubMed  CAS  Google Scholar 

  19. Glennon RA, Lucki I. Behavioural models of serotonin receptor activation. In: Sanders-Bush E, editor. The serotonin receptors. Clifton, NJ: Humana Press; 1988. pp 253–93.

    Google Scholar 

  20. Lucki I. 5-HT1 receptors and behaviour. Neurosci Biobehav Rev. 1992;16:83–93.

    Article  PubMed  CAS  Google Scholar 

  21. Giordano J, Rogers L. Putative mechanisms of buspironeinduced antinociception in the rat. Pain. 1992;50:365–72.

    Article  PubMed  CAS  Google Scholar 

  22. Trouillas P, Takayanagi T, Hallett M, et al. International cooperative ataxia rating scale for pharmacological assessment of the cerebellar syndrome. The ataxia neuropharmacology committee of the world federation of neurology. J Neurol Sci. 1997;145:205–11.

    Article  PubMed  CAS  Google Scholar 

  23. Zung WWK. A self-rating depression scale. Arch Gen Psychiat. 1963;12:63–70.

    Google Scholar 

  24. Wieland S, Fischette CT, Lucki I. Effect of chronic treatments with tandospirone and imipramine on serotoninmediated behavioral responses and monoamine receptors. Neuropharmacology. 1993;32:561–573.

    Article  PubMed  CAS  Google Scholar 

  25. Pike VW, MaCarron JA, Lammerstma AA, et al. First delineation of 5-HT1A receptors in human brain with PET and [11C]WAY 100635. Eur J Pharmacol. 1995;283:R1–3.

    Article  PubMed  CAS  Google Scholar 

  26. Burnet PW, Eastwood SL, Lacey K, Harrison PJ. The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain. Brain Res. 1995;676:157–68.

    Article  PubMed  CAS  Google Scholar 

  27. Miquel MC, Doucet E, Riad M, Adrien J, Verge D, Hamon M. Effect of the selective lesion of serotoninergic neurons on the regional distribution of 5-HT1A receptor mRNA in the rat brain. Brain Res Mol Brain Res. 1992; 14:357–62.

    Article  PubMed  CAS  Google Scholar 

  28. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38:1083–152.

    Article  PubMed  CAS  Google Scholar 

  29. Maura G, Raiteri M. Serotonin 5-HT1D and 5-HT1A receptors respectively mediate inhibition of glutamate release and inhibition of cyclic GMP production in rat cerebellum in vitro. J Neurochem. 1996;66:203–09.

    Article  PubMed  CAS  Google Scholar 

  30. Maura G, Roccatagliata E, Ulivi M, Raiteri M. Serotoninglutamate interaction in rat cerebellun: Involvement of 5-HT1 and 5-HT2 receptors. Eur J Pharmacol. 1988:31–8.

  31. Raiteri M, Maura G, Barzizza A. Activation of presynaptic 5-hydroxytryptamine1-like receptors on glutamatergic terminals inhibits N-methyl-D Aspartate-induced cyclic GMP production in rat cerebellar slices. J Pharmacol Exp Ther. 1991; 257:1184–8.

    PubMed  CAS  Google Scholar 

  32. Darrow EJ, Strahlendorf HK, Strahlendorf JC. Response of cerebellar Purkinje cells to serotonin and the 5-HT1A agonists 8-OH-DPAT and ipsapironein vitro. Eur J Pharmacol. 1990;175:145–53.

    Article  PubMed  CAS  Google Scholar 

  33. Monte TL, Rieder CR, Tort AB, et al. Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study. Acta Neurol Scand. 2003;107:207–10.

    Article  PubMed  CAS  Google Scholar 

  34. Bier JC, Dethy S, Hildebrand J, Jacquy J, Manto M, Martin JJ, Seeldrayers P. Effects of the oral form of ondansetron on cerebellar dysfunction. A multi-center double-blind study. J Neurol. 2003;250:693–7.

    Article  PubMed  CAS  Google Scholar 

  35. Drevets WC, Frank E, Price JC, et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry. 1999;46:1375–87.

    Article  PubMed  CAS  Google Scholar 

  36. Sargent PA, Kjaer KH, Bench CJ, et al. Brain serotonin 1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry. 2000;57:174–80.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Asako Takei.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Takei, A., Hamada, T., Yabe, I. et al. Treatment of cerebellar ataxia with 5-HT1A agonist. Cerebellum 4, 211–215 (2005). https://doi.org/10.1080/14734220500222318

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1080/14734220500222318

Key words

Navigation